Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short Communication

Co-infection of SARS-CoV-2 with other respiratory viruses and performance of lower respiratory tract samples for the diagnosis of COVID-19

Sonia Burrel, Pierre Hausfater, Martin Dres, Valérie Pourcher, Charles-Édouard Luyt, Elisa Teyssou, Cathia Soulé, Vincent Calvez, Anne-Geneviève Marcelin, David Boutolleau

Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for coronavirus disease 2019 (COVID-19) emerged in Wuhan, China, in December 2019 (Zhu et al., 2020). A few studies have reported proportions of SARS-CoV-2 co-infections with other respiratory viruses (range, 0–20%) (Chen et al., 2020; Kim et al., 2020; Leuzinger et al., 2020; Lin et al., 2020a; Wee et al., 2020). Furthermore, lower respiratory tract (LRT) samples have been found to significantly improve the efficiency of diagnosis compared with upper respiratory tract (URT) samples for non-SARS-CoV-2 respiratory infections (Branche et al., 2014; Falsey et al., 2012).

This study, performed during the early outbreak period of COVID-19 and the seasonal epidemics of other respiratory viral infections, aimed to describe the extent of co-infections of SARS-CoV-2 with other respiratory viruses. A second objective of this study was to compare the diagnostic performances of URT and LRT samples for SARS-CoV-2 infection. From 25 January to 29 March...
2020, all URT and LRT samples collected from patients with suspected COVID-19 received in the virology laboratory of Pitié-Salpêtrière University Hospital (Paris, France) were tested for SARS-CoV-2 and other respiratory viruses. The study population consisted of hospitalised symptomatic adults. All patients had respiratory symptoms, as mentioned in the definition of possible COVID-19 cases at that time in France. SARS-CoV-2 RNA was detected by real-time RT-PCR (Corman et al., 2020). SARS-CoV-2 loads were estimated with cycle threshold (Ct) values. Other respiratory viruses were tested with the FilmArray<sup>b</sup> RP2plus (BIOMERIEUX): influenza virus, respiratory syncytial virus, metapneumovirus, adenovirus, parainfluenza virus, non-SARS-CoV-2 coronavirus, and rhinovirus/enterovirus. For statistical analyses, continuous variables were expressed as median (range) and categorical variables as numbers (percentages). Comparisons were performed using Mann-Whitney U test (continuous variables) and Chi-squared test (categorical variables). *P* < 0.05 was considered to be statistically significant.

During the study period, 1423 consecutive hospitalised patients (677 males, 746 females, median age 50 years) were included. Patients originated from Pitié-Salpêtrière hospital (n = 1167) or from other close hospitals (n = 256). Most of patients from Pitié-Salpêtrière hospital were hospitalised within 10 days after the onset of symptoms and were tested for SARS-CoV-2 and other respiratory viruses within 24 h of admission. Among patients from Pitié-Salpêtrière hospital, 233/1167 (20.0%) were hospitalised in the intensive care unit (ICU). Detection rates of respiratory viruses among patients were: 724 (50.9%) negative for respiratory viruses, 398 (28.0%) positive for other respiratory viruses, 280 (19.7%) positive for SARS-CoV-2, and 21 (1.5%) positive for SARS-CoV-2 and other respiratory viruses (Table 1). Among patients negative for SARS-CoV-2 (n = 1122), those who were positive for other respiratory viruses were statistically younger than those who were negative (median, 39 vs. 52 years, *p* > 0.0001). Conversely, among patients who were positive for SARS-CoV-2 (n = 301), no significant age difference was observed between those who were positive for other respiratory viruses and those who were negative (median, 56 vs. 54 years, not significant). Among the 21 patients co-infected with SARS-CoV-2, other respiratory viruses that were detected were non-SARS-CoV-2 coronavirus (n = 6), influenza virus (n = 5), adenovirus (n = 3), rhinovirus/enterovirus (n = 3), para-influenza virus (n = 3), and adenovirus + rhinovirus/enterovirus (n = 1). Four of 21 (19.0%) co-infected patients were hospitalised in ICU, which was significantly lower than the 113/280 (46.4%) patients infected with SARS-CoV-2 alone (*p* = 0.020) (Table 1).

A total of 1160 URT and 379 LRT samples were collected. The detection rate of SARS-CoV-2 was significantly higher in LRT (203, 53.6%) than in URT (1160, 13.4%; *p* < 0.0001). Paired samples from URT and LRT were obtained from 117 (8.2%) patients. Among the 85 patients who were positive for SARS-CoV-2, 52 (68.2%) showed concordant positive results in URT and LRT samples (Figure 1A), but SARS-CoV-2 load was at least 1 log higher in LRT than in URT samples for 38 patients (65%) (Figure 1B). Moreover, 26 (30.6%) patients showed discordant SARS-CoV-2 results, with negative URT and positive LRT samples (Figure 1A). A similar profile was observed for the 32 patients infected with other respiratory viruses: concordant positive results in URT and LRT for 12 (37.5%), while 18 (56.3%) showed discordant results, with negative URT and positive LRT samples (Figure 1A). The proportion of patients positive for SARS-CoV-2 with discordant results was significantly lower than the one of patients positive for other respiratory viruses with discordant results: 30.6% vs. 56.3% (*p* = 0.012).

In the present study, 7% (21/301) of SARS-CoV-2-positive patients were co-infected with other respiratory viruses. This co-infection rate is similar to some previously reported rates (range, 0–6.5%) (Chen et al., 2020; Leuzinger et al., 2020; Lin et al., 2020a), but lower than others (up to 20%) (Kim et al., 2020). This might be due to different study populations or potential spatiotemporal variations in viral epidemiology. In particular, it is very likely that the lockdown in France, which started on 17 March and lasted until 11 May 2020, had no (or very little) influence on the circulation of respiratory viruses during the present study performed from 25 January to 29 March 2020. In line with previous studies, different types of other respiratory viruses were detected together with SARS-CoV-2 among co-infected patients, including non-SARS-CoV-2 coronavirus, influenza virus, adenovirus, rhinovirus/enterovirus, and parainfluenza virus (Kim et al., 2020; Leuzinger et al., 2020; Lin et al., 2020a; Wee et al., 2020). Patients co-infected with SARS-CoV-2 and other respiratory viruses did not significantly differ in age and gender from those infected with SARS-CoV-2 alone, as previously described (Kim et al., 2020). Among ICU patients, the proportion of co-infected patients was significantly lower than the one infected with SARS-CoV-2 alone, possibly indicating that co-infection with other respiratory viruses might not worsen the severity of SARS-CoV-2–associated respiratory disease, which was in accordance with a previous study (Wee et al., 2020). The current study found a higher efficiency of LRT than URT samples for COVID-19 diagnosis, with a significantly higher rate of detection of SARS-CoV-2 and a 1 log higher SARS-CoV-2 load for the majority of infected patients. This discrepancy could be partly explained by the variability in the delay between the onset of symptoms and the sampling among patients. However, this higher diagnostic performance of LRT samples for respiratory infections, including COVID-19, has been previously reported (Branche et al., 2014; Falsey et al., 2012; Lin et al., 2020b; Wang et al., 2020). In the current study, the proportion of patients positive for SARS-CoV-2 with discordant

| Table 1 Characteristics of suspected COVID-19 patients, according to respiratory virological findings. |
|---------------------------------------------------------------|
| SARS-CoV-2 (−) | Other respiratory viruses (−) | SARS-CoV-2 (−) | Other respiratory viruses (+) | SARS-CoV-2 (+) | Other respiratory viruses (−) | SARS-CoV-2 (+) | Other respiratory viruses (+) |
| No. (%) of patients | 724 (50.9%) | 398 (28.0%) | 280 (19.7%) | 21 (1.5%) |
| Demographic characteristics |  |
| Male | 328 (45.3%) | 178 (44.7%) | 160 (57.1%) | 11 (52.4%) |
| Female | 396 (54.7%) | 220 (55.3%) | 120 (42.9%) | 10 (47.6%) |
| Median age (y) (range) | 52 (0–103) | 39 (0–101) | 56 (12–94) | 54 (30–94) |
| Hospitalisation in ICU<sup>a</sup> |  |
| Yes | 89 (15.3%) | 27 (8.4%) | 113 (46.7%) | 4 (19.0%) |
| No | 493 (84.7%) | 295 (91.6%) | 129 (53.3%) | 17 (81.0%) |
| Abbreviations: (−), negative; (+), positive; ICU, intensive care unit; y, years. |
|<sup>a</sup> | *p* < 0.0001 (Mann–Whitney U test). |
|<sup>b</sup> | Rates of hospitalisation in ICU only for the patients from Pitié-Salpêtrière University Hospital (n = 1167). |
|<sup>c</sup> | *p* = 0.020 (Chi-squared test). |
Results was significantly lower than the one of patients who were positive for other respiratory viruses with discordant results. Those different profiles of compartmentalisation of PCR positivity within the respiratory tract may suggest some differences in pathophysiology of SARS-CoV-2 infection compared with infections by other respiratory viruses.

In conclusion, the detection of other respiratory viruses in patients during this epidemic period could not rule out SARS-CoV-2 co-infection, and LRT samples increased the accuracy of diagnosis of viral respiratory infections, including COVID-19.

Conflict of interest

DB and PH received lecture honorarium and fees for congress transportation and registration from Biomerieux. MD received honorarium for fees for travel expenses from Lungpacer. CEL received lecture honorarium from Biomerieux. Other authors have no conflict of interest to declare.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Ethical approval

Due to the observational and retrospective nature of the study, the need for specific informed consent from individual patients was not required. All data were generated from routine standard clinical management of the patients. An informed consent to the treatment of personal data was acquired upon hospital admission from the patients or their legal representatives.

Acknowledgements

We thank all healthcare workers involved in the diagnosis and treatment of COVID-19 patients in Pitié-Salpêtrière University Hospital (Paris, France).
References

Branche AR, Walsh EE, Formica MA, Falsey AR. Detection of respiratory viruses in sputum from adults by use of automated multiplex PCR. J Clin Microbiol 2014;52:3590–6.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13.

Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020;25:1–8.

Falsey AR, Formica MA, Walsh EE. Yield of sputum for viral detection by reverse transcriptase PCR in adults hospitalized with respiratory illness. J Clin Microbiol 2012;50:21–4.

Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. JAMA 2020;323:2085–6.

Leuzinger K, Roloff T, Gosert R, Sogaard K, Naegle K, Reitsch K, et al. Epidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 emergence amidst community-acquired respiratory viruses. J Infect Dis 2020;222:1270–9.

Lin D, Liu L, Zhang M, Hu Y, Yang Q, Guo J, et al. Co-infections of SARS-CoV-2 with multiple common respiratory pathogens in infected patients. Sci China Life Sci 2020a;63:606–9.

Lin C, Xiang J, Yan M, Li H, Huang S, Shen C. Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19). Clin Chem Lab Med 2020b;58:1089–94.

Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020;323:1843–4.

Wee LE, Ko KKK, Ho WQ, Kwok GTC, Tan TT, Wijaya L. Community-acquired viral respiratory infections amongst hospitalized inpatients during a COVID-19 outbreak in Singapore: co-infection and clinical outcomes. J Clin Virol 2020;128:104436.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–33.